Health
State Government Welcomes 30% Trade Margin Cap on Major Cancer Drugs to Ease Financial Burden
The state government has welcomed the new policy imposing a 30% trade margin cap on key cancer drugs, aiming to provide significant financial relief to patients.
The state government has welcomed a new policy that imposes a 30% trade margin cap on major cancer drugs, aiming to provide significant financial relief to patients suffering from cancer.
Under the trade margin cap, manufacturers and distributors will be limited to a 30% profit margin on these drugs, which is expected to lower the retail prices and reduce the overall cost burden on patients.
The policy is part of the state's broader effort to make essential medicines more affordable and is expected to help patients who otherwise face high out‑of‑pocket expenses for cancer treatment.
By capping the trade margin, the government hopes to ensure that savings are passed on to patients and that the availability of life‑saving drugs is not compromised by high profit margins.
Under the trade margin cap, manufacturers and distributors will be limited to a 30% profit margin on these drugs, which is expected to lower the retail prices and reduce the overall cost burden on patients.
The policy is part of the state's broader effort to make essential medicines more affordable and is expected to help patients who otherwise face high out‑of‑pocket expenses for cancer treatment.
By capping the trade margin, the government hopes to ensure that savings are passed on to patients and that the availability of life‑saving drugs is not compromised by high profit margins.